The amount of the third component of complement (C3) bound to red cells of patients with the cold agglutinin syndrome was determined by a quantitative assay, measuring the fixation of the first component of complement by anti-C3. Abrupt reduction in the serum concentration of cold agglutinin by plasmapheresis markedly decreased the hemolytic rate, but the amount of C3 bound to circulating cells...

The last 2 decades have seen great progress in understanding the pathogenesis of cold agglutinin disease (CAD) and development effective therapies. Cold agglutinins can cause hemolytic anemia as well peripheral circulatory symptoms such acrocyanosis. We distinguish CAD, a well-defined clinicopathologic entity, from secondary syndrome. This review addresses histopathologic, immune phenotypic, mo...

This study investigated the clonal nature of cold agglutinin disease in a series of nine patients, which included the benign or idiopathic form as well as cases with an underlying lymphoma. Surface marker phenotyping and karyotypic analysis were performed on peripheral blood lymphocytes. An increased proportion of B cells was found in four cases and in three of these patients a monoclonal B cel...

Dr Gyger and colleagues, in reply to our work on granulocyte colony-stimulating factor (G-CSF) bone marrow (BM) purging, have pointed out three aspects of the problem: the possible negative balance of marrow cells after short-term G-CSF administration, the need for at least two cytokines for priming BM stem cells (BMSC), and the probable contamination of BM harvest. Overall, we agree on each of...

Objectives Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia that may manifest in complement-mediated chronic anemia, profound fatigue, and transient agglutination-mediated circulatory symptoms. This study compared the healthcare resource utilization (HRU) patients with CAD matched non-CAD comparison cohort using national Danish health registry data.Methods All cases w...